The company Roche Pharma AG is sending out information on the risk of haemorrhage and rhabdomyolysis as well as new recommendations on dose modifications when taking Cotellic® (cobimetinib). Prior to initiating treatment, serum CPK and creatinine levels should be determined and subsequently monitored monthly during treatment or as clinically indicated. In cases of increased serum CPK levels, it must be evaluated whether the signs and symptoms are due to rhabdomyolysis or whether other causes are present.

Download DHPC / Information letter PDF, 230KB, File is accessible